Wegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring

Novo Nordisk announced a significant restructuring, including 9,000 job cuts (11.5% of its workforce), to achieve $1.3 billion in annual savings as it confronts intense competition from Eli Lilly and slowing sales of its blockbuster drugs, Wegovy and Ozempic. This strategic overhaul, aimed at enhancing efficiency and reallocating resources amid substantial market share loss and a 46% year-to-date stock decline, will incur 9 billion DKK in Q3 one-off costs and has led to a lowered profit growth outlook for the year, though analysts view the move as a necessary step for long-term competitiveness.

Analysis

Novo Nordisk is undertaking a significant corporate restructuring, cutting 9,000 jobs, or 11.5% of its workforce, in a decisive move to generate approximately $1.3 billion in annual savings. This action, initiated by new CEO Mike Doustdar, is a direct response to intensifying competition from rival Eli Lilly and a material deceleration in sales growth and market share for its blockbuster drugs Wegovy and Ozempic, particularly in the U.S. market. The company will absorb a one-off restructuring cost of 9 billion DKK in the third quarter, which has prompted a downgrade of its full-year operating profit growth guidance to 4-10% from 10-16%. It is critical to note this revision is attributed solely to the one-off charge, not a change in the underlying business outlook. The move comes after the stock has plummeted nearly 46% year-to-date, erasing hundreds of billions in market value from its 2023 peak. While the restructuring signals significant operational and competitive headwinds, analysts view it as a necessary measure to streamline operations and reallocate resources, potentially setting a stronger foundation for future performance.

Key Decisions for Investors

• Investors should view this aggressive restructuring as a pivotal moment; the 46% year-to-date stock decline could present a value opportunity if the $1.3 billion in annual savings successfully translates into improved long-term margins and competitiveness.
• The scale of the job cuts underscores the severity of the competitive threat from Eli Lilly and the slowdown in key product sales, warranting close scrutiny of future earnings reports for evidence that the company can stabilize market share.
• Focus on leading indicators beyond the one-off restructuring charge, such as U.S. prescription volume for Wegovy and Ozempic, and monitor management commentary on how the cost savings will be reinvested to defend its core therapy areas.